Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA orphan designation, according to a post on the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01
- Bristol Myers announces EC approval of Breyanzi
- 2seventy Bio price target lowered to $5 from $6 at Morgan Stanley